How babesiosis is treated in conventional medical care.

Severe disease is more than a high parasite percentage.

Babesiosis can become life-threatening when hemolysis and systemic inflammation produce organ injury. Severe complications include acute respiratory distress syndrome, shock, renal failure, liver dysfunction, disseminated intravascular coagulation, severe anemia, heart failure, splenic infarction or rupture, and neurologic complications.

IDSA suggests considering red-cell exchange transfusion in selected patients with severe disease, particularly when parasitemia is very high (often cited as >10%) or when severe hemolysis or major pulmonary, renal, or hepatic compromise is present. Parasitemia alone should not be interpreted without the clinical picture; the decision belongs in a hospital setting with infectious-disease, hematology and transfusion-medicine expertise.

Why the spleen and immune system matter

The spleen is central to filtering abnormal or infected red blood cells and mounting an effective response to intraerythrocytic parasites. People without a spleen are at increased risk for severe babesiosis. Persistent or relapsing infection is also disproportionately reported in people with B-cell malignancies, rituximab exposure, or other major immune suppression.

Persistent and relapsing babesiosis

A 2008 case-control study examined 14 immunocompromised patients with persistent or relapsing B. microti infection despite repeated treatment and compared them with 46 controls whose infection cleared after one standard course. Every persistent-case patient was immunosuppressed; many had B-cell lymphoma, had received rituximab, or were asplenic. Eleven ultimately cleared infection after multiple courses, and the authors reported that these highly immunocompromised patients generally required at least six weeks of therapy, including treatment after parasites were no longer visible on smear.

That experience is not a reason to extend treatment indefinitely in everyone. IDSA specifically distinguishes immunocompetent patients—who usually do not need continued parasite testing once symptoms resolve—from highly immunocompromised patients who may require prolonged monitoring and treatment.

Antimicrobial resistance

Relapse during prolonged treatment can reflect impaired host immunity, inadequate drug exposure, or acquired parasite resistance. Molecular case reports have documented mutations in the atovaquone-binding region of cytochrome b and in ribosomal targets associated with macrolide resistance. Resistance is one reason prolonged or refractory cases should be managed by clinicians experienced in babesiosis rather than by simply repeating the same regimen without reassessment.

Tafenoquine: promising, but not routine first-line therapy

Tafenoquine is an antimalarial drug that has attracted interest for relapsing babesiosis. A 2024 case series reported five highly immunocompromised patients treated with tafenoquine-containing regimens. Four achieved clearance; one patient receiving tafenoquine alone relapsed. The authors concluded that tafenoquine can be a useful adjunct in highly immunocompromised patients with relapsing B. microti infection. This is emerging evidence from a small case series—not a replacement for established first-line therapy or a basis for self-treatment.